REJECTED: FDA snubs Forest/Gedeon Richter antipsychotic cariprazine
This article was originally published in Scrip
Executive Summary
The FDA has rejected the new drug application (NDA) for Forest Laboratories' and Gedeon Richter atypical antipsychotic cariprazine to treat schizophrenia and as an acute treatment for manic or mixed episodes associated with bipolar I disorder in adults.